Source author record

Emilie B. Lindkvist

Emilie B. Lindkvist appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

2works
4topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2022arXiv

A one-size-fits-all artificial pancreas for people with type 1 diabetes based on physiological insight and feedback control

We propose a model-free artificial pancreas (AP) for people with type 1 diabetes. The algorithmic parameters are tuned to a virtual population of 1,000,000 individuals, and the AP repeatedly estimates the basal and bolus insulin requirements necessary for maintaining normal blood glucose levels. Therefore, the AP can be used without healthcare personnel or engineers customizing the algorithm to each user. The estimates are based on bodyweight, measurements from a continuous glucose monitor (CGM), and estimates of the meal carbohydrate contents. In a virtual clinical trial with all 1,000,000 individuals (i.e., a Monte Carlo closed-loop simulation), the AP achieves a mean time in range of more than 87% and almost 89% of the participants satisfy several glycemic targets.

preprint2022arXiv

Nonlinear Model Predictive Control and System Identification for a Dual-hormone Artificial Pancreas

In this work, we present a switching nonlinear model predictive control (NMPC) algorithm for a dual-hormone artificial pancreas (AP), and we use maximum likelihood estimation (MLE) to identify model parameters. A dual-hormone AP consists of a continuous glucose monitor (CGM), a control algorithm, an insulin pump, and a glucagon pump. The AP is designed with a heuristic to switch between insulin and glucagon as well as state-dependent constraints. We extend an existing glucoregulatory model with glucagon and exercise for simulation, and we use a simpler model for control. We test the AP (NMPC and MLE) using in silico numerical simulations on 50 virtual people with type 1 diabetes. The system is identified for each virtual person based on data generated with the simulation model. The simulations show a mean of 89.3% time in range (3.9-10 mmol/L) and no hypoglycemic events.